AR124599A1 - Constructos de expresión y usos de estos - Google Patents
Constructos de expresión y usos de estosInfo
- Publication number
- AR124599A1 AR124599A1 ARP220100043A ARP220100043A AR124599A1 AR 124599 A1 AR124599 A1 AR 124599A1 AR P220100043 A ARP220100043 A AR P220100043A AR P220100043 A ARP220100043 A AR P220100043A AR 124599 A1 AR124599 A1 AR 124599A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- isolated polynucleotide
- cell
- vector
- lipid nanoparticle
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 abstract 9
- 108091033319 polynucleotide Proteins 0.000 abstract 9
- 239000002157 polynucleotide Substances 0.000 abstract 9
- 150000002632 lipids Chemical class 0.000 abstract 5
- 239000002105 nanoparticle Substances 0.000 abstract 4
- 102000015696 Interleukins Human genes 0.000 abstract 2
- 108010063738 Interleukins Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Optics & Photonics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente divulgación se refiere a un polinucleótido aislado que comprende una secuencia que codifica una molécula de interleucina (IL)-12, y un sistema de administración que puede transportar los polinucleótidos. La divulgación también incluye métodos para fabricar los polinucleótidos y métodos de tratamiento mediante el uso de los mismos. Reivindicación 1: Un polinucleótido aislado que comprende una molécula de ácido nucleico que codifica una subunidad b de una proteína IL-12 (IL-12b), caracterizado porque la molécula de ácido nucleico comprende una secuencia de nucleótido que es al menos aproximadamente 75%, al menos aproximadamente 76%, al menos aproximadamente 77%, al menos aproximadamente 78%, al menos aproximadamente 79%, al menos aproximadamente 80%, al menos aproximadamente 81%, al menos aproximadamente 82%, al menos aproximadamente 83%, al menos aproximadamente 84%, al menos aproximadamente 85%, al menos aproximadamente 86%, al menos aproximadamente 87%, al menos aproximadamente 88%, al menos aproximadamente 89%, al menos aproximadamente 90%, al menos aproximadamente 91%, al menos aproximadamente 92%, al menos aproximadamente 93%, al menos aproximadamente 94%, al menos aproximadamente 95%, al menos aproximadamente 96%, al menos aproximadamente 97%, al menos aproximadamente 98%, al menos aproximadamente 99% o aproximadamente 100% idéntica a la secuencia establecida en la SEQ ID Nº 51, SEQ ID Nº 52, SEQ ID Nº 53, SEQ ID Nº 54, SEQ ID Nº 55, SEQ ID Nº 56, SEQ ID Nº 57, SEQ ID Nº 58, SEQ ID Nº 59, SEQ ID Nº 60, SEQ ID Nº 61, SEQ ID Nº 62, SEQ ID Nº 63, SEQ ID Nº 64, SEQ ID Nº 65, SEQ ID Nº 66, SEQ ID Nº 67, SEQ ID Nº 68, SEQ ID Nº 69, SEQ ID Nº 70, SEQ ID Nº 71, SEQ ID Nº 72, SEQ ID Nº 73, SEQ ID Nº 74, o la SEQ ID Nº 75. Reivindicación 92: Un vector caracterizado porque comprende el polinucleótido aislado de una cualquiera de las reivindicaciones 1 a 91. Reivindicación 93: Una nanopartícula lipídica caracterizada porque comprende (I) el polinucleótido aislado de una cualquiera de las reivindicaciones 1 a 92, y (II) uno o más tipos de lípidos. Reivindicación 109: Una composición farmacéutica que comprende el polinucleótido aislado de una cualquiera de las reivindicaciones 1 a 91, el vector de la reivindicación 92 o la nanopartícula lipídica de una cualquiera de las reivindicaciones 93 a 108 y un portador farmacéuticamente aceptable. Reivindicación 111: Una célula que comprende el polinucleótido aislado de una cualquiera de las reivindicaciones 1 a 91, el vector de la reivindicación 92 o la nanopartícula lipídica de una cualquiera de las reivindicaciones 93 a 108. Reivindicación 112: La célula de la reivindicación 111, que es una célula in vitro, una célula ex vivo o una célula in vivo. Reivindicación 114: Un método para producir una proteína IL-12 caracterizado porque comprende poner en contacto una célula con el polinucleótido aislado de una cualquiera de las reivindicaciones 1 a 91, el vector de la reivindicación 92 o la nanopartícula lipídica de una cualquiera de las reivindicaciones 93 a 108.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135501P | 2021-01-08 | 2021-01-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124599A1 true AR124599A1 (es) | 2023-04-12 |
Family
ID=80222240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100043A AR124599A1 (es) | 2021-01-08 | 2022-01-10 | Constructos de expresión y usos de estos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240166707A1 (es) |
| EP (1) | EP4274846A1 (es) |
| JP (1) | JP2024503000A (es) |
| KR (1) | KR20230129479A (es) |
| CN (1) | CN116917309A (es) |
| AR (1) | AR124599A1 (es) |
| AU (1) | AU2022205679A1 (es) |
| CA (1) | CA3204373A1 (es) |
| CO (1) | CO2023009063A2 (es) |
| IL (1) | IL304118A (es) |
| MX (1) | MX2023008002A (es) |
| TW (1) | TW202241931A (es) |
| WO (1) | WO2022150712A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024108109A1 (en) * | 2022-11-18 | 2024-05-23 | Trustees Of Boston University | Self-replicating rna and uses thereof |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| CA1327358C (en) | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1999024595A1 (en) | 1997-11-12 | 1999-05-20 | The Brigham And Women's Hospital, Inc. | The translation enhancer element of the human amyloid precursor protein gene |
| US7468275B2 (en) | 2000-01-28 | 2008-12-23 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
| AU2001231171B2 (en) | 2000-01-28 | 2007-01-04 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
| IL161100A0 (en) | 2001-09-28 | 2004-08-31 | Max Planck Gesellschaft | Identification of novel genes coding for small temporal rnas |
| US7265096B2 (en) | 2002-11-04 | 2007-09-04 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| EP1670918B1 (en) | 2003-09-26 | 2009-11-11 | Merck Serono SA | Leader sequences for use in production of proteins |
| WO2007025008A2 (en) | 2005-08-24 | 2007-03-01 | The Scripps Research Institute | Translation enhancer-element dependent vector systems |
| EP2487260B1 (en) | 2006-01-05 | 2015-07-08 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis and treatment of solid cancers |
| CN103361424A (zh) | 2006-01-05 | 2013-10-23 | 俄亥俄州立大学研究基金会 | 胰腺内分泌和腺泡肿瘤中的微小rna表达异常 |
| EP2522747A1 (en) | 2006-03-02 | 2012-11-14 | The Ohio State University | MicroRNA expression profile associated with pancreatic cancer |
| US20090131348A1 (en) | 2006-09-19 | 2009-05-21 | Emmanuel Labourier | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| AU2007314212B2 (en) | 2006-11-01 | 2014-05-29 | The Govt. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services | MicroRNA expression signature for predicting survival and metastases in Hepatocellular carcinoma |
| CN101622349A (zh) | 2006-12-08 | 2010-01-06 | 奥斯瑞根公司 | 作为治疗性干预靶标的miR-21调节的基因和途径 |
| US8415096B2 (en) | 2007-05-23 | 2013-04-09 | University Of South Florida | Micro-RNAs modulating immunity and inflammation |
| US20090099034A1 (en) | 2007-06-07 | 2009-04-16 | Wisconsin Alumni Research Foundation | Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers |
| CN101918594A (zh) | 2007-11-30 | 2010-12-15 | 俄亥俄州立大学研究基金会 | 肺癌中外周血中的微rna表达特征谱和靶向 |
| EP2610340B1 (en) | 2007-12-11 | 2014-10-01 | The Scripps Research Institute | Compositions and methods related to mRNA translational enhancer elements |
| US20090263803A1 (en) | 2008-02-08 | 2009-10-22 | Sylvie Beaudenon | Mirnas differentially expressed in lymph nodes from cancer patients |
| EP2254668A4 (en) | 2008-02-28 | 2012-08-15 | Univ Ohio State Res Found | MICRORNA SIGNATURES ASSOCIATED WITH HUMAN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND THEIR USE |
| EP2112235A1 (en) | 2008-04-24 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| WO2010018563A2 (en) | 2008-08-12 | 2010-02-18 | Rosetta Genomics Ltd. | Compositions and methods for the prognosis of lymphoma |
| WO2010055487A2 (en) | 2008-11-13 | 2010-05-20 | Koninklijke Philips Electronics N.V. | Compositions and methods for micro-rna expession profiling of colorectal cancer |
| US20120053224A1 (en) | 2008-12-10 | 2012-03-01 | Universitat Regensburg | Compositions and methods for micro-rna expression profiling of cancer stem cells |
| US20120264626A1 (en) | 2009-05-08 | 2012-10-18 | The Ohio State University Research Foundation | MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof |
| WO2011076143A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expression profiling of lung cancer |
| WO2011076142A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
| EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
| WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
| EP2354246A1 (en) | 2010-02-05 | 2011-08-10 | febit holding GmbH | miRNA in the diagnosis of ovarian cancer |
| US20130059015A1 (en) | 2010-03-11 | 2013-03-07 | H. Lee Moffitt Cancer Center & Research Institute | Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response |
| WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
| US20130230884A1 (en) | 2010-07-16 | 2013-09-05 | John Chaput | Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation |
| WO2012151212A1 (en) | 2011-05-01 | 2012-11-08 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
| WO2012153187A2 (en) | 2011-05-06 | 2012-11-15 | Xentech | Markers for cancer prognosis and therapy and methods of use |
| EP2732052B1 (en) | 2011-07-15 | 2016-11-16 | Leo Pharma A/S | Diagnostic microrna profiling in cutaneous t-cell lymphoma (ctcl) |
| WO2013033640A1 (en) | 2011-09-01 | 2013-03-07 | Allegro Diagnostics Corp. | Methods and compositions for detecting cancer based on mirna expression profiles |
| CA2846436A1 (en) | 2011-09-23 | 2013-03-28 | Universitat Stuttgart | Serum half-life extension using immunoglobulin binding domains |
| US20140243240A1 (en) | 2011-10-26 | 2014-08-28 | Georgetown University | microRNA EXPRESSION PROFILING OF THYROID CANCER |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| EP2918275B1 (en) | 2013-12-13 | 2016-05-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| US20170136132A1 (en) | 2014-06-19 | 2017-05-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| EP3326641B1 (en) * | 2015-04-22 | 2019-06-26 | CureVac AG | Rna containing composition for treatment of tumor diseases |
| AU2017268397B2 (en) | 2016-05-18 | 2023-07-06 | Modernatx, Inc. | Polynucleotides encoding interleukin-12 (IL12) and uses thereof |
| EP3589308A1 (en) | 2017-02-28 | 2020-01-08 | Sanofi | Therapeutic rna |
| WO2020123716A1 (en) * | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
-
2022
- 2022-01-10 TW TW111101009A patent/TW202241931A/zh unknown
- 2022-01-10 JP JP2023541286A patent/JP2024503000A/ja active Pending
- 2022-01-10 CA CA3204373A patent/CA3204373A1/en active Pending
- 2022-01-10 MX MX2023008002A patent/MX2023008002A/es unknown
- 2022-01-10 US US18/260,831 patent/US20240166707A1/en active Pending
- 2022-01-10 EP EP22703119.2A patent/EP4274846A1/en active Pending
- 2022-01-10 AU AU2022205679A patent/AU2022205679A1/en active Pending
- 2022-01-10 CN CN202280018742.XA patent/CN116917309A/zh active Pending
- 2022-01-10 WO PCT/US2022/011841 patent/WO2022150712A1/en active Application Filing
- 2022-01-10 KR KR1020237026740A patent/KR20230129479A/ko unknown
- 2022-01-10 AR ARP220100043A patent/AR124599A1/es unknown
-
2023
- 2023-06-28 IL IL304118A patent/IL304118A/en unknown
- 2023-07-06 CO CONC2023/0009063A patent/CO2023009063A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202241931A (zh) | 2022-11-01 |
| AU2022205679A1 (en) | 2023-07-06 |
| CO2023009063A2 (es) | 2023-07-21 |
| EP4274846A1 (en) | 2023-11-15 |
| JP2024503000A (ja) | 2024-01-24 |
| KR20230129479A (ko) | 2023-09-08 |
| IL304118A (en) | 2023-09-01 |
| CN116917309A (zh) | 2023-10-20 |
| WO2022150712A1 (en) | 2022-07-14 |
| MX2023008002A (es) | 2023-08-25 |
| CA3204373A1 (en) | 2022-07-14 |
| US20240166707A1 (en) | 2024-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shlomai | The structure and replication of kinetoplast DNA | |
| ES2927175T3 (es) | Método de producción de micropartículas | |
| US20220288240A1 (en) | Use of Thermostable RNA Polymerases to Produce RNAs Having Reduced Immunogenicity | |
| US9353153B2 (en) | Cyclic RNA and protein production method | |
| US20220243244A1 (en) | Compositions and methods for in vivo synthesis of unnatural polypeptides | |
| JPS59501096A (ja) | 構造遺伝子の製造および発現 | |
| ES2056366T3 (es) | Dna-polimerasa de t7. | |
| AR124599A1 (es) | Constructos de expresión y usos de estos | |
| CN110036107A (zh) | TCRα归巢核酸内切酶变体 | |
| BRPI0410562B8 (pt) | proteína de veículo e seu método de produção em uma planta, ácido nucleico isolado, vetor de expressão e célula hospedeira | |
| Kung et al. | Studies on the Role of Ribosomal Proteins L7 and L12 in the in Vitro Synthesis of β-Galactosidase | |
| AR125199A1 (es) | Edición génica cish de linfocitos infiltrantes de tumores y usos de los mismos en inmunoterapia | |
| CO2024002315A2 (es) | Sistemas de edición de gen que comprenden una guía de arn dirigida a estatmina 2 (stmn2) y usos de los mismos | |
| AR127629A1 (es) | Moléculas de anticuerpo y conjugados | |
| CN101497863A (zh) | 一种制备N-末端乙酰化的胸腺素α1的方法及其专用工程菌 | |
| Hayase et al. | Microheterogeneity of N-acetyl-β-d-hexosaminidase of bull epididymis | |
| KR20100085763A (ko) | 닭 인터페론-알파 유전자를 발현하는 살모넬라 균주 및 이를 함유하는 조성물 | |
| WO2019239751A1 (ja) | 細胞移植用組成物及び細胞移植方法 | |
| AR045408A1 (es) | Genes y polipeptidos relacionados con cancer de colon humano | |
| RU2707525C1 (ru) | Рекомбинантная плазмида, экспрессирующая клонированный ген шаперона HFQ Vibrio cholerae, и штамм Escherichia coli - суперпродуцент шаперона HFQ Vibrio cholerae | |
| AR012837A1 (es) | Beta-glucosidasas: metodos para su obtencion, preparaciones con las mismas y sus correspondientes usos | |
| AR116403A1 (es) | Nucleasa pacas9 | |
| AR124277A1 (es) | Proteínas de fusión de interleucina-2-fc y métodos de uso | |
| CN106432425B (zh) | 花姬蛙抗氧化肽及其基因和在制药中的应用 | |
| AR125379A1 (es) | Un fab anti-tslp con estabilidad mejorada |